Cancer/testis antigens have emerged as attractive targets for cancer immunotherapy. Clinical studies have targeted MAGE-A3， a prototype antigen that is a member of the MAGE-A family of antigens， in melanoma and lung carcinoma. However， these studies have not yet had a significant impact due to poor CD8 T-cell immunogenicity， platform toxicity， or perhaps limited target antigen availability. In this study， we develop an improved MAGE-A immunogen with cross-reactivity to multiple family members.
Cancer/testis antigens have emerged as attractive targets for cancer immunotherapy. Clinical studies have targeted MAGE-A3， a prototype antigen that is a member of the MAGE-A family of antigens， in melanoma and lung carcinoma. However， these studies have not yet had a significant impact due to poor CD8 T-cell immunogenicity， platform toxicity， or perhaps limited target antigen availability. In this study， we develop an improved MAGE-A immunogen with cross-reactivity to multiple family members.
